116026-94-9

Basic information

• Product Name: 2-N-Boc-amino-3-formylpyridine
• Synonyms: 2-N-BOC-AMINO-3-FORMYLPYRIDINE;2-BOC-AMINO-3-FORMYLPYRIDINE;(3-FORMYL-PYRIDIN-2-YL)-CARBAMIC ACID TERT-BUTYL ESTER;TERT-BUTYL 3-FORMYLPYRIDIN-2-YLCARBAMATE;REF DUPL: 2-N-Boc-amino-3-formylpyridine;tert-butyl N-(3-forMylpyridin-2-yl)carbaMate;Carbamic acid, N-(3-formyl-2-pyridinyl)-, 1,1-dimethylethyl ester
• CAS NO: 116026-94-9
• Molecular Formula: C₁₁H₁₄N₂O₃
• Molecular Weight: 222.24
• Product Categories: Pyridines
• Mol File: 116026-94-9.mol

Chemical Properties

• Melting Point: 109-111 °C
• Boiling Point: 310 °C
• Flash Point: 141 °C
• Appearance: White to off-white powder
• Density: 1.212
• Vapor Pressure: 0.000618mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 12.05±0.70(Predicted)
• CAS DataBase Reference: 2-N-Boc-amino-3-formylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-N-Boc-amino-3-formylpyridine(116026-94-9)
• EPA Substance Registry System: 2-N-Boc-amino-3-formylpyridine(116026-94-9)

Safety Data

• Hazardous Substances Data: 116026-94-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry Research:
2-N-Boc-amino-3-formylpyridine is used as a key intermediate for the synthesis of various organic compounds due to its unique structure and functional groups. The Boc-protected amine and formyl group allow for selective reactions and the formation of diverse chemical products.
Used in Pharmaceutical Production:
2-N-Boc-amino-3-formylpyridine is used as a building block in the development of pharmaceuticals. Its versatile properties enable the creation of new drug candidates with potential therapeutic applications. The Boc group can be selectively removed when needed, allowing for further functionalization and modification of the molecule.
Used in Synthesis of Bioactive Molecules:
2-N-Boc-amino-3-formylpyridine is employed as a starting material for the synthesis of bioactive molecules with potential applications in medicine and biology. Its unique structure and functional groups facilitate the development of novel compounds with specific biological activities.
Used in the Production of Advanced Materials:
2-N-Boc-amino-3-formylpyridine is utilized in the synthesis of advanced materials, such as polymers and coordination compounds, with potential applications in various industries, including electronics, energy, and environmental protection. Its versatile properties allow for the design and development of materials with tailored properties and functions.

InChI:InChI=1/C11H14N2O3/c1-11(2,3)16-10(15)13-9-8(7-14)5-4-6-12-9/h4-7H,1-3H3,(H,12,13,15)

Upstream product

• 2591-86-8 N-Formylpiperidine 
• 38427-94-0 N-(tert-butoxycarbonyl)-2-aminopyridine 
• 504-29-0 2-aminopyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 594-19-4 tert.-butyl lithium 

Downstream Products

• 7521-41-7 2-Aminonicotinaldehyde 
• 54856-61-0 2-amino-5-chloropyridine-3-carboxaldehyde 
• 1433992-81-4 3-benzyl-4,5-dihydro-1H-pyrido[2,3-e][1,4]diazepin-2(3H)-one 
• 1433992-82-5 tert-butyl 3-benzyl-2-oxo-2,3-dihydro-1H-pyrido[2,3-e][1,4]diazepine-4(5H)-carboxylate 
• 1433992-83-6 tert-butyl 3-benzyl-2-thioxo-2,3-dihydro-1H-pyrido[2,3-e][1,4]diazepine-4(5H)-carboxylate 
• 1433992-84-7 tert-butyl 3-benzyl-2-(methylthio)-3H-pyrido[2,3-e][1,4]diazepine-4(5H)-carboxylate 
• 1433997-71-7 (Z)-tert-butyl 3-benzyl-2-(2,2-dimethoxyethylimino)-2,3-dihydro-1H-pyrido[2,3-e][1,4]diazepine-4(5H)-carboxylate 
• 1433992-85-8 tert-butyl 7-benzyl-5H-imidazo[1,2-a]pyrido[3,2-f][1,4]diazepine-6(7H)-carboxylate 
• 1434044-44-6 7-benzyl-6,7-dihydro-5H-imidazo[1,2-a]pyrido[3,2-f][1,4]diazepine hydrochloride 
• 1433991-77-5 C₂₆H₂₁N₅O₂S 
• 521984-94-1 1-methyl-2-phenyl-1H-pyrrolo-[2,3-b]pyridine 
• 945607-66-9 benzyl-[3-(2,2-dichlorovinyl)-pyridin-2-yl]-amine 
• 945608-15-1 3-iodo-1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridine 
• 1009104-86-2 C₁₉H₂₀Cl₂N₂O₂ 

Relevant articles and documents

An efficient synthesis of 2-amino-5-chloro-3-pyridinecarbox-aldehyde and 5-amino-2-chloro-4-pyridinecarboxaldehyde

Efficient synthetic routes to the title compounds 2-amino-5-chloro-3- pyridinecarboxaldehyde (1a) and 5-amino-2-chloro-4-pyridinecarboxaldehyde (1b) are reported. Both compounds are important substrates in the synthesis of naph-thyridine derivatives. Copyright by Walter de Gruyter Berlin Boston.

SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)

The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administration of these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof as well as pharmaceutical compositions comprising said compounds as an active ingredient.

New Straightforward Quinoline Synthesis from the Mannich Reaction of α-Ketohydrazones

The addition of α-ketohydrazones to 2-acetamidobenzaldehyde proceeds efficiently in the presence of N-benzylpiperazine to afford in good to high yields the expected Mannich adducts; these are easily converted to quinoline derivatives under acidic conditio

Tyrosine kinase inhibitors

The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such

Inhibitors of Cyclic AMP Phosphodiesterase. 3. Synthesis and Biological Evaluation of Pyrido and Imidazolyl Analogues of 1,2,3,5-Tetrahydro-2-oxoimidazoquinazoline

Hybridization of structural elements of 1,2,3,5-tetrahydro-2-oxoimidazoquinazoline ring system common to the cyclic AMP (cAMP) phosphodiesterase (PDE) inhibitors lixazinone (RS-82856,1) and anagrelide (3) with complementary features of other PDE inhibitor cardiotonic agents prompted the design and synthesis of the title compounds 7a-d, 11, 12, and 13a,b.The necessary features of these compounds were determined within the framework of the proposed active-site models for the high affinity form of cAMP PDE inhibited by cGMP (type IV).Evaluation of these targets, both in vitro as inhibitors of platelet or cardiac type IV PDE or in vivo as inotropic agents in the pentobarbital-anesthetized dog model of congestive heart failure, showed that these structure possessed negligibly enhanced activities over the parent heterocyclic system, and remained significantly inferior to 1 in all respects.This difference is ascribed to the absence of the N-cyclohexyl-N-methylbutyramidyl-4-oxy side chain of 1.The proposal that the acidic lactam-type functionality, common to the type IV PDE inhibitor inotropic agents such as 4-6 and 8-10, mimics the polarizable cyclic phosphate moiety of cAMP suggested that the side chain of 1 may function as an effective surrogate for selected characteristics of the adenine portion of cAMP.However, the results of this study show that incorporation of adenine-like hydrogen-bonding functionalities common to other type IV PDE inhibitors into the 1,2,3,5-tetrahydro-2-oxoimidazoquinazoline system did not enhance activity to the levels observed for 1 analogues.These observations, coupled with the kinetic pattern of inhibition of type IV PDE observed for 1 and analogues, suggest that access to a secondary, lipophilic-tolerant binding site, possibly coincident with the adenine binding domain, and adjacent to the catalytic ribose-phosphate binding site of platelet and cardiac type IV PDE, is responsible for the increased potency of these compounds.